Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Cut Drug Prices by 1.35% on Medical Cost Basis; No Special Rule for Adjustment Rate This Time
December 22, 2021
- AZ’s COVID-19 Drug to Be Reviewed with Priority if Filed in Japan: Senior Vice Minister
December 22, 2021
- Gist of FY2022 Drug Pricing Reform
December 22, 2021
- Look into Relationship Between COVID-19 Vaccination and Adverse Events: MHLW Panel
December 22, 2021
- Mochida’s Inhaled Treprostinil Gets Orphan Status
December 22, 2021
- Japan Expected to Cut Drug, Medical Device Prices by 160 Billion Yen on National Offers Basis
December 21, 2021
- MHLW Panel OKs “Specific-Use” Drug Designation for Dexmedetomidine
December 21, 2021
- Japan Likely to Expand PMP Coverage for Add’l Indications, Set 4-Year Grace Period for Spillover Exclusion: 2022 Reform
December 21, 2021
- Noxafil Contraindicated for Combined Use with Lonasen, Belsomra
December 20, 2021
- PM Kishida Vows to Move Up Booster, Offer COVID-19 Pill as Japan Girds for Omicron
December 20, 2021
- MSD’s Molnupiravir Up for PAFSC Review on Dec. 24
December 20, 2021
- Moderna COVID-19 Booster to Start from December 17
December 17, 2021
- Japan Approves Moderna Vaccine for COVID-19 Booster
December 16, 2021
- LDP Study Group Proposal Calls for 2%-Plus Adjustment Rate for 2022 Drug Price Revision
December 16, 2021
- Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
December 16, 2021
- Japan Panel OKs Moderna COVID-19 Vaccine for Booster Use
December 16, 2021
- Japan to Boost Pharma Startup Ecosystem via VC Certification Program, Allocates 50 Billion Yen in FY2021 Extra Budget
December 15, 2021
- Aducanumab Up for Japan Advisory Panel Review on December 22
December 15, 2021
- MHLW Calls for Lifting of Shipment Restrictions for 130 Generic API/Specifications after Survey Finds YOY Rise in Supplies
December 14, 2021
- Doctor, Pharmacist Reps Call for Expanding Fees for Biosimilars: Chuikyo
December 13, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…